JP2011088897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011088897A5
JP2011088897A5 JP2010253233A JP2010253233A JP2011088897A5 JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5 JP 2010253233 A JP2010253233 A JP 2010253233A JP 2010253233 A JP2010253233 A JP 2010253233A JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5
Authority
JP
Japan
Prior art keywords
apo
ligand
formulation
metal ions
divalent metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010253233A
Other languages
English (en)
Other versions
JP2011088897A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011088897A publication Critical patent/JP2011088897A/ja
Publication of JP2011088897A5 publication Critical patent/JP2011088897A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 製剤に存在する一つ又は複数の二価金属イオンの濃度がＡｐｏ−２リガンドに対して＜２Ｘモル比である、前記Ａｐｏ−２リガンド及び前記一つ又は複数の二価金属イオンを含んでなる製剤。
JP2010253233A 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 Pending JP2011088897A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001506824A Division JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Publications (2)

Publication Number Publication Date
JP2011088897A JP2011088897A (ja) 2011-05-06
JP2011088897A5 true JP2011088897A5 (ja) 2012-02-02

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
JP2010253233A Pending JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Country Status (12)

Country Link
US (3) US7855066B1 (ja)
EP (3) EP2339003A3 (ja)
JP (2) JP5118796B2 (ja)
KR (1) KR100674528B1 (ja)
CN (2) CN101633692A (ja)
AU (3) AU6338200A (ja)
CA (1) CA2377585A1 (ja)
ES (1) ES2392392T3 (ja)
IL (2) IL147029A0 (ja)
MX (1) MXPA01013236A (ja)
NZ (2) NZ515990A (ja)
WO (1) WO2001000832A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2339003A3 (en) * 1999-06-28 2011-10-19 Genentech, Inc. Apo-2 ligand substitutional variants
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
ES2351786T3 (es) * 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
JP5014116B2 (ja) 2004-03-11 2012-08-29 ジェネンテック， インコーポレイテッド ポリペプチドの精製
JP5237638B2 (ja) 2004-08-06 2013-07-17 ジェネンテック， インコーポレイテッド バイオマーカーを用いたアッセイおよび方法
WO2006017859A2 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
ES2380119T3 (es) 2005-08-16 2012-05-08 Genentech, Inc. Sensibilidad apoptótica a APO2L/TRAIL analizando la expresión de GalNac-T14 en células/tejidos
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP2019518713A (ja) * 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変ｔｒａｉｌ
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0257956B2 (en) 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
EP0397687B1 (en) 1987-12-21 1994-05-11 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
WO1992003478A1 (en) 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AU1757092A (en) 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
KR100510234B1 (ko) * 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997046686A2 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
EA199900256A1 (ru) 1996-10-03 2000-02-28 Байотерапиз, Инк. Нуклеотидная и белковая последовательность маммастатина и способы применения
CA2665133A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
SK288559B6 (sk) 1997-04-16 2018-05-02 Amgen, Inc. Nukleová kyselina, polypeptid, expresný vektor a hostiteľská bunka; proteín viažuci osteoprotegerín a spôsob jeho prípravy, protilátka a liečivo na prevenciu alebo liečenie chorôb kostí
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
DK1009817T3 (da) 1997-08-26 2010-01-18 Genentech Inc RTD-receptor
WO1999036535A1 (en) * 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
EP2339003A3 (en) * 1999-06-28 2011-10-19 Genentech, Inc. Apo-2 ligand substitutional variants
WO2001018055A1 (en) 1999-09-10 2001-03-15 Eli Lilly And Company Flint analog compounds and formulations thereof
WO2001018041A2 (en) 1999-09-10 2001-03-15 Eli Lilly And Company Flint proteins and formulations thereof
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
ES2351786T3 (es) * 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Similar Documents

Publication Publication Date Title
JP2011088897A5 (ja)
JP2011506530A5 (ja)
JP2013546230A5 (ja)
JP2014530840A5 (ja)
JP2013140343A5 (ja)
JP2014500291A5 (ja)
JP2012516348A5 (ja)
JP2011510778A5 (ja)
JP2012500946A5 (ja)
PT2699545T (pt) Novos derivados amino-pirrolínicos, sua utilização na prevenção e/ou tratamento do síndrome metabólico
CL2013001596A1 (es) Proceso de purificacion y estabilizacion de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); y uso de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3).
EP2353384A3 (en) Disinfectant formulations that remain liquid at low temperature
CN302031649S (zh) 高磁活化净水器
TH113394B (th) หน้าตัดโลหะ
TH119094B (th) หน้าตัดโลหะ
TH116308B (th) หน้าตัดโลหะ
TH118401B (th) หน้าตัดโลหะ
TH119582B (th) หน้าตัดโลหะ
TH113272B (th) จาน
TH113273B (th) จาน
TH113274B (th) จาน
CN302011816S (zh) 加湿器(hq-603da)
TH116544B (th) หัวเตาแก๊ส
TH119263B (th) หน้าตัดโลหะ
TH119255B (th) หน้าตัดโลหะ